Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial03: Dato-DXd + Platinum vs Gemcitabine + Platinum in la/mUC Post-EV/Pembrolizumab
NCT07129993Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in urothelial carcinoma (UC) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Overall Response Rate at 34 months, Progression-Free Survival at 38 months and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07129993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129993.